A new study indicates that 95 percent of breast cancer cases in women under 50 are being missed by current National Health Service (NHS) screening protocols in the UK. Researchers from the University of Cambridge and The Institute of Cancer Research, London, found that the existing guidelines, primarily based on family history, are insufficient for identifying young women at high risk of developing the disease. The findings were published in the British Journal of Cancer.
Cases of breast cancer in women under 50 have been increasing in the UK, rising by approximately 1.4 percent annually. While the disease is treatable when detected early, younger women are more likely to be diagnosed at later stages, leading to a nearly 40 percent higher mortality rate for women under 40 compared to those over 40.
The study analyzed data from over 1,000 women under 50 recruited between 2004 and 2011. It compared the effectiveness of the National Institute for Health and Care Excellence (NICE) criteria, which GPs use for referrals, against a more comprehensive risk model known as BOADICEA. The NICE criteria heavily relies on family history, yet only about three-quarters of women under 50 with breast cancer have a family history of the disease. Under these guidelines, only 1.4 percent of young women who developed breast cancer were identified as high-risk and referred for specialist assessment. In contrast, the BOADICEA model, which incorporates lifestyle, reproductive history, and genetic information, correctly identified 26.5 percent of these cases.
Dr. Juliet Usher-Smith, lead author of the study, stated that the current NICE criteria are missing a significant portion of women under 50 who will develop breast cancer. She emphasized the need to re-evaluate these criteria to enable earlier intervention when treatment options are more effective or even preventive measures can be taken.
However, other experts have raised concerns about the study's interpretation and limitations. Dr. Paul Pharoah, Professor of Cancer Epidemiology, argued that the NICE criteria are designed for women who present with concerns about family history and are therefore not relevant for the majority of younger women who do not have such a history. He noted that 80 percent of breast cancers in women aged 20 to 50 occur in those without a family history, making the current guidelines predictably underperform for this broader group.
Researchers acknowledge that expanding risk assessments to all women under 50, as suggested by the BOADICEA model, would significantly increase costs and lead to more referrals, many of whom might not develop cancer. Professor Montserrat Garcia-Closas highlighted the challenge of balancing the ease of implementation of current criteria with the potential benefits of more accurate risk classification, noting that a comprehensive assessment including genetic testing could place a substantial burden on resources.
Another limitation noted by experts is that all participants in the study were white. Breast cancer affects roughly one in seven women in the UK. While most cases occur in women over 50, the incidence in younger women has been rising, now accounting for one in five breast cancer cases in Britain, a 20 percent increase since the early 1990s. Factors such as rising obesity, alcohol consumption, changes in reproductive patterns, and improved detection methods are believed to contribute to this trend.